COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases21/08/2025
-   
  Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference21/08/2025
-   
  Pyxis Oncology to Participate in September Investor and Industry Conferences21/08/2025
-   
  InflaRx Announces Participation in September Investor Conferences21/08/2025
-   
  BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.21/08/2025
-   
  Kraig Biocraft Laboratories Announces Commencement of Full Operations at Second Production Rearing Center in Southeast Asia21/08/2025
-   
  BioCryst to Present at Upcoming Investor Conference21/08/2025
-   
  Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book21/08/2025
-   
  Unleashing the Spirit of Adventure: Breckenridge Distillery Launches Mountain Shot, a Bold New Mushroom-Infused Elixir21/08/2025
-   
  I-Mab to Participate in September Investor Conferences21/08/2025
-   
  BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer21/08/2025
-   
  Castle Biosciences to Participate in Upcoming Investor Conferences21/08/2025
-   
  Skye Bioscience to Participate in Upcoming Investment and Medical Conferences21/08/2025
-   
  Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield21/08/2025
-   
  Cannara annonce la modification et l’augmentation de la facilité de crédit accordée par BMO afin de soutenir l’expansion de ses installations à Valleyfield21/08/2025
-   
  Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®21/08/2025
-   
  Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®21/08/2025
-   
  Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%21/08/2025
-   
  Interim report H1 202521/08/2025
Pages